Alto Neuroscience, Inc. Depreciation
Alto Neuroscience, Inc. (ANRO) reported Depreciation of $200.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-12
- Alto Neuroscience, Inc. depreciation for the quarter ending 2026-06-30 was $200.00K, a 100.00% increase year-over-year.
- Alto Neuroscience, Inc. depreciation for the quarter ending 2026-03-31 was $184.00K, a 7.60% increase year-over-year.
- Alto Neuroscience, Inc. depreciation for the quarter ending 2025-12-31 was $157.00K, a 7.65% decline year-over-year.
- Alto Neuroscience, Inc. depreciation for the quarter ending 2025-09-30 was $200.00K, a 0.00% change year-over-year.
- Alto Neuroscience, Inc. depreciation for fiscal 2025 was $661.00K, a 31.67% increase from fiscal 2024.
- Alto Neuroscience, Inc. depreciation for fiscal 2024 was $502.00K.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|
| 2026-06-30 | $200.00K 10-Q · filed 2026-08-12 | $368.00K 10-Q · filed 2026-08-12 | $541.00K derived: sum of 3 quarters · filed 2026-08-12 | $741.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $184.00K 10-Q · filed 2026-05-13 | $341.00K derived: sum of 2 quarters · filed 2026-05-13 | $541.00K derived: sum of 3 quarters · filed 2026-05-13 | $641.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $157.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $357.00K derived: sum of 2 quarters · filed 2026-03-16 | $457.00K derived: sum of 3 quarters · filed 2026-08-12 | $661.00K 10-K · filed 2026-03-16 |
| 2025-09-30 | $200.00K 10-Q · filed 2025-11-12 | $300.00K derived: sum of 2 quarters · filed 2026-08-12 | $504.00K 10-Q · filed 2025-11-12 | $641.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $100.00K 10-Q · filed 2026-08-12 | $340.00K 10-Q · filed 2026-08-12 | $441.00K derived: sum of 3 quarters · filed 2026-08-12 | $641.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $171.00K 10-Q · filed 2026-05-13 | $341.00K derived: sum of 2 quarters · filed 2026-05-13 | $541.00K derived: sum of 3 quarters · filed 2026-05-13 | |
| 2024-12-31 | $170.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $370.00K derived: sum of 2 quarters · filed 2026-03-16 | $502.00K 10-K · filed 2026-03-16 | |
| 2024-09-30 | $200.00K 10-Q · filed 2025-11-12 | $332.00K 10-Q · filed 2025-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |